Mihad Ibrahim

Ms. Mihad Ibrahim


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MIMihad Ibrahim
Mihad Ibrahim
WAWaad Hussein Abuwatfa
Waad Hussein Abuwatfa
NANahid Awad
Nahid Awad
Rana SabouniRana Sabouni
Rana Sabouni
GHGhaleb Adnan Husseini
Ghaleb Adnan Husseini
Doxorubicin (DOX) is one of the most widely used anthracycline anticancer drugs due to its high efficacy and evident antitumoral activity on several cancer types. However, its effective utilization is hindered by the adverse side effects associated with its administration, the detriment to the patients’ quality of life, and general toxicity to healthy fast-dividing cells. Thus, delivering DOX to the tumor site encapsulated inside nanocarrier-based systems is an area of research that has garnered colossal interest in targeted medicine. Nanoparticles can be used as vehicles for the localized delivery and release of DOX, decreasing the effects on neighboring healthy cells and providing more control over the drug’s release and distribution. This review presents an overview of DOX-based nanocarrier delivery systems, covering loading methods, release rate, and the cytotoxicity of liposomal, micellar, and metal organic frameworks (MOFs) platforms.